The traditional approach to the discovery of new anticancer drugs involves the use of disease-related screens for a wide gamut of chemical types, followed by systematic chemical manipulation of active compounds. The compounds can subsequently be evaluated for antineoplastic activity, toxic side effects, and pharmacokinetic properties, and they can be developed into therapies for cancer treatment. Increasingly, and in striking contrast, defined selective macromolecular targets are being used as the basis for new drug discovery. The importance of this trend will increase as the results of studies on the molecular basis of oncogenesis are applied to cancer diagnosis and cure. The enormous advances in recombinant DNA techniques over the past decade have led to the identification of key proteins that are intimately involved in the regulation of cancer growth and invasion control at the level of gene expression. In particular, the pivotal role of specific transcription factors in certain cancers, either as mutants or in overexpressed levels, highlights them as rational targets for chemotherapeutic intervention. The large volume of data available on the molecular anatomy of transcription factors and the biochemical pathways that modulate their function offer opportunities for the design of structure-based, small organic molecules targeting oncogenic transcription factors (oncogene or tumor suppressor gene products) selectively, thus creating powerful new pharmaceuticals that inhibit malignant cell growth and tumor metastasis.
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STRUCTURE-FUNCTION RELATIONSHIPS OF TRANSCRIPTION FACTORS
The Transcriptional Machinery A brief overview of eukaryotic transcriptional control is warranted before we discuss transcription factors as targets for drug design. The regulation of transcription of protein-coding genes involved in normal cellular metabolism or correlated with cancer development and progression is achieved by an ensemble of proteins whose central component is the enzyme RNA polymerase II (pol II). Although pol II has an intrinsic capacity to synthesize RNA, it is unable to efficiently recognize gene promoters or transcription initiation sites and accurately initiate transcription on its own. To accomplish this, it requires the close collaboration of a battery of accessory proteins, collectively termed transcription factors. Transcription factors are generally divided into two groups: the basal transcription factors and the gene-specific transcription factors (1) . Basal transcription factors are ubiquitous, DNAor non-DNA-binding proteins essential for the transcription of all protein-coding genes, which recruit and align pol II at the core promoter region of the gene. This region encompasses the so-called TATA box (a recognition sequence around which basal transcription factors/pol II amalgamate) and the transcription initiation site ( Fig. 1) (2) . Gene-specific transcription factors, which are only required for a subset of genes transcribed by pol II, recognize and bind to a second promoter region (typically composed of multiple short-6-12 bp-cis-acting DNA sequence elements) located within a few hundred base pairs upstream from the transcription initiation site or positioned many kilobases away (in which case it is called enhancer) (1) . These control regions may bind numerous, different gene- (TFIIB, TFIID-TBP-TAFs, TFIIE, and TFIIH (Fig. 1) . Consequently, different transcription factor homodimers and heterodimers may recognize the same or related DNA sequences and this allows the generation of combinatorial diversity in the regulation of transcription (1) .
The DNA-binding and dimerization domains of transcription factors are necessary but not sufficient for transcriptional activity. Yet another domain, the so-called transactivation (or, in the case of negatively acting factors, transrepression) domain, rich in negatively charged (acidic) amino acids or glutamine/proline residues, is required for interacting (directly or indirectly) with one or more components of the transcriptional apparatus (pol II and basal transcription factors) and thus facilitating (or inhibiting) transcription initiation from a given gene promoter ( Fig. 1) (1,9). Several transcription factors appear to have multiple transactivation domains that are of more than one type. Detailed information about the tertiary structure of these domains is difficult to obtain, as they are loosely ordered in solution and adopt a rigid conformation only when they contact their appropriate target within the transcription complex.
Regulation of Transcription Factor Activity The function of any of the aforementioned transcription factor domains may be subject to regulation by reversible, covalent modifications induced by a broad spectrum of physical and chemical stimuli (e.g., mechanical forces, osmotic stress, ultraviolet light, growth factors/mitogens, cytokines, hormones, etc.). Among them, protein (de)phosphorylation at specific sites is the post-translational modification of choice when rapid modulation of transcription factor activity in response to changes in environmental conditions, metabolic activity, and growth signals is required (10) . Alterations in the phosphorylation state of transcription factors may affect their function either positively or negatively by eliciting conformational changes that expose, mask, or remodel a particular domain/ region of the protein (11) . Since phosphorylation of an acceptor amino acid (serine, threonine, or tyrosine) changes its charge to negative, a decrease in the phosphorylation of the DNA-binding domain would increase its net positive charge and thus enhance the interaction of the DNAbinding domain with the negatively charged phosphodiester backbone of the DNA duplex. On the other hand, increased phosphorylation of amino acids within or in the vicinity of the dimerization or the transactivation (transrepression) domains could augment the ability of the transcription factor to homo-or heterodimerize or stimulate (inhibit) transcription ( Fig. 1 ) (11, 12) . Phosphorylation can also affect the function of transcription factors in other fashions. It is now well established that the subcellular localization and stability of several transcription factors (thus their steady-state level) are subject to regulatory influences by phosphorylation events occuring at specific parts of the molecule; these places usually overlap with other defined domains of the transcription factor (12, 13) .
Ligand binding is another mode of transcription factor activation that is typical for the large superfamily of steroid-thyroid-retinoid nuclear hormone receptors. Upon binding its ligand (hormone), a typical steroid receptor activates expression of particular target genes by binding to its specific response element in a promoter or enhancer. Finally, a variety of different (cytoplasmic and nuclear non-DNA-binding) proteins interacting specifically with transcription factors may control their activity in indirect ways, adding another dimension to the regulatory repertoire and signal integration. Tethering of such proteins to transcription factors may exert a diverse range of functions, e.g., serving as a bridge between the transcription factor and the basal transcriptional machinery or unrelated transcription factors; stabilizing the DNA-bound form; changing the specificity of the target recognition sequence; sequestering the factor in an inactive complex (dissociation of the complex by signaldependent (de)phosphorylation of the anchor protein allows translocation of the factor to the nucleus); enhancing its degradation, etc. (13) .
A single transcription factor may be regulated by one or more systems at multiple steps along the way to transcription activation. There is probably a hierarchy in the importance of the control steps for a particular transcription factor, some of which may mainly serve for "fine tuning" by coupling to other regulatory pathways.
ONCOGENIC TRANSCRIPTION FACTORS
Cancer often results from the aberrant activation of specific genes known as oncogenes, which encode components of the cellular machinery that regulates normal growth processes (14, 15) .
Either overexpression of these genes or mutations that lead to the formation of a more active product can result in deregulated control of cellular proliferation and conversion to the malignant phenotype (16) . Considering their importance in the control of cell behavior, it is not unexpected that a large group of oncogenes (currently one-third of the known oncogenes) have been found to encode transcription factors (or nuclear proteins that regulate transcription factors) engaged in the expression of genes whose products are required to initiate the cascade of events that lead to passage through the cell cycle (17) . Moreover, a number of developmental decisions as well as the execution of coordinated programs of differentiation of different specialized cell types are under the control of oncogenic transcription factors, which are often the final targets (integration centers) of signal transduction pathways (18) . The concentration and activity of oncogenic transcription factors are normally tightly controlled at several points (and by one or more systems) down the pathway to their ultimate action in gene transcription, and they can be greatly affected by a wide spectrum of extracellular signals. Several of these transcription factors can themselves function as oncoproteins (5, 13, 16, 19 (22) (23) (24) . These molecular "cut-and-paste" maneuvers give rise to hybrid transcription factors that possess the DNA-binding specificity of one parental protein and the activation characteristics of another. In some instances it may be necessary for only one of the genes to contribute a biochemical activity (DNA binding, transactivation) to the hybrid protein. The contribution from the other gene may be passive, such as disruption or replacement of a regulatory domain/region.
The myc oncogene (which encodes a bHLH/ ZIP transcription factor, which, together with its partner Max, is required for cell proliferation, prevention of differentiation in response to mitogenic stimuli, and induction of apoptosis) was identified as a site of chromosomal translocation in Burkitt's lymphomas in humans (where its expression is dramatically increased) and as an amplified locus in some human tumors (17, 25) .
The Myc protein family (including c-Myc, NMyc, and L-Myc) serves as an archetype for the activation of an oncogenic transcription factor by chromosomal rearrangement. This model has since been successfully applied to the study of genes that are associated with chromosomal translocations in human leukemias, lymphomas, and several solid tumors. The characterization of transcription factor-coding oncogenes that are rearranged in chromosomal translocations includes the following (17, 18, 26 , and references therein): hox-11 (which encodes a homeodomain-bearing transcription factor whose expression is activated by translocation to the T-cell receptor locus in cases of acute childhood T-cell leukemia); tal-1 (which encodes a bHLH transcription factor whose expression is stimulated in acute lymphoblastic leukemia); bcl-3 (a member of the IKB family, which interacts with the NFKB transcription factors [see below], whose aberrant expression is involved in some B-cell chronic leukemias); ets (encoding the Ets transcription factor, which is fused to the platelet-derived growth factor receptor in patients with chronic myelomonocytic leukemia); erg (an ets-related gene, which is activated by translocation in human myeloid leukemias); fli-1 (another etsrelated gene, which is fused to the transcription factor-coding gene ews in Ewing's sarcomas); the retinoic acid receptor a (RARa) gene (which encodes a transcription factor of the steroid-thyroid-retinoid nuclear hormone receptor gene superfamily, which is fused to the zinc fingercontaining PML transcription factor in all cases of promyelocytic leukemia); E2A (which encodes a bHLH transcription factor, which is fused to the homeodomain-containing Pbx-1 transcription factor in pre-B-cell leukemias); aml-1 (involved in a chromosomal translocation, which fuses it to the transcription factor-coding gene mtg-8, present in a large fraction of cases of acute myeloid leukemia); pax-3 (which participates in dermomyotome formation during development and is fused to the gene encoding the FKHR transcription factor in alveolar rhabdomyosarcomas); hrx/enl and hrx/af-4 (fused transcription factorcoding genes generated by translocations in some acute leukemias); and many others. These genes are of special interest because of their direct association with specific human tumors.
Other A distinct class of genes, known as anti-oncogenes or tumor suppressor genes, encode proteins that normally function in a manner opposite that of oncogenes and act to restrain cellular growth. The mutational inactivation or deletion of these genes can therefore result in cancer (15, 27) . A number of anti-oncogenes of this type have been defined, and four of them (this number continues to grow) encode transcription factors (17, 28) . Three of these, p53 (which participates in the cellular response to DNA damage and acts as a tetramer), its newly discovered structural relative p73 (acting also as an oligomer), and the Wilms' tumor gene product (WT1, a zinc finger-containing transcription factor), function by binding directly to their target DNA and either up-regulating the expression of growth-inhibitory/apoptosis-promoting genes (p53), or down-regulating the expression of growth-inducing genes (WT1) (17, 29, 30) . More research is definitely needed to determine the role(s) of p73 in cell growth control (31) . In contrast, the product of the retinoblastoma susceptibility gene (pRb) exerts its growth-inhibitory effects primarily via protein-protein interactions with other DNA-binding transcription factors (e.g., E2F), preventing them from stimulating the transcription of genes that encode growth-promoting products (e.g., Myc, Myb, thymidine kinase) (17, 32, 33) . Interestingly (for the purpose of this review), association of the human papillomavirus-types 16 Small-molecule drug-transcription factor recognition is achieved through the molecular surface structures and the implicit interaction energies with the most commonly associated minor conformational changes. The factors contributing to complementarity include the size and shape of interacting surfaces (geometric properties) as well as special features of a surface structure, such as charge distribution and hydrophobicity (gross chemical properties). A common molecular docking procedure can be divided into two stages. The first is a selection of a population of complexes by geometric docking in which surface structures of two interacting molecules are matched with each other, allowing minor conformational changes implicitly on the basis of complementarity in size and close packing in shape. Searching for the optimal match in a chosen solution space (which has to be delicately balanced to maintain both computational efficiency and completeness in searching) is accomplished by the use of elaborated combinatorial algorithms (40) .
After the potential solutions are generated in a chosen solution space in the first stage of the docking procedure, the precision of matching two surface structures (i.e., the "fitness" of candidate ligands [drugs] into the targeted transcription factor site) is evaluated in the second stage from the energetic point of view. This stage utilizes a detailed knowledge of the atomic interactions involved in molecular association, much of which has been obtained by high-resolution Xray crystallographic and/or NMR analyses of macromolecular complexes (transcription factor alone and, ideally, of the DNA-transcription factor or the transcription factor-other protein complexes). Since the putative drug is not present in the solved structure, one must be "docked" into the target site by considering the energy of drug binding (41) (42) (43) (44) . Any calculation of the binding energy of the simulated docking of a drug to a transcription factor target site must take into account the "cavitation" effect (the loss of bound solvent from the drug and targeted transcription factor sites), van der Waals/hydrophobic effects, electrostatic (hydrogen bonding, charge-charge/dipole-dipole interactions) and induced electrostatic effects, conformational effects (induced fit) in the target, and the entropic effect resulting from the restriction of several degrees of freedom (e.g., vibrational, rotational, translational) in the drug molecule. Since there is no method to accurately calculate each of these effects, approximations must be made taking into consideration that multiple binding modes of the drug to its target transcription factor site are also possible. Even in the absence of the 3-D structure of the target transcription factor, drug design that takes into account the 3-D flexibility of candidate ligands can help revolutionize the discovery of new compounds (38) .
The great advantage of structure-based design is that rather than trying to find molecules that adopt suitable geometries for a single binding mode, the entire transcription factor site can be explored, allowing a diversity of transcription factor domain/region-drug interactions to be considered. A number of different methodologies and algorithms have been adopted for docking organic molecule databases into known target structures (44) (45) (46) .
De novo Drug Design Based on Target Transcription Factor 3-D Structures
The most ambitious route to designing appropriate transcription factor inhibitors is to create completely new compounds as drugs. The new molecules may be based on existing inhibitors or antagonists, or they may be created from scratch, atom by atom. At least three distinct approaches to de novo design (the design of novel compounds against a target based on structural information about that target) have emerged: directed design, random design, and grid-based design. For each of these, the de novo paradigm can be split into two phases: structure generation (either atom by atom or by linking together existing fragments and templates), and structure evaluation (whereby the structures are assessed and prioritized using a scoring scheme). Each of these methodologies has its own strengths and weaknesses, depending on whether one wishes to build molecules from linked fragments that have been matched to transcription factor site points, from linked fragments grown from a seed point using a potential energy function, or from linked fragments built using irregular lattices of previously docked molecules. Today, one of the most exciting developments in de novo design is the use of the known 3-D structure of a transcription factor as a "virtual" screen against a combinatorial library, allowing the de novo design methodology to generate diversity focused toward a specific transcription factor site (DNAbinding/oligomerization/transactivation domain or other functionally defined regions). Indeed, there are a number of molecules in clinical trials that have been assisted by de novo design philosophies (38, 47) .
Mode of Action of Putative Transcription Factor Inhibitors
The modular architecture of gene-specific transcription factors predisposes them to the effects of small-molecule drugs. An oncogenic transcription factor inhibitor may act by binding to the DNA-binding domain, the dimerization domain(s), the transactivation (transrepression) domain(s), or other defined protein/ligand(e.g., hormone)-binding regions mediating a specific biochemical function (see Figs. 2 and 3) . The mode of action of the drug in all these cases could be simple steric hindrance of either the requisite DNA-protein or protein-protein/ligand interactions, resulting in a loss of function along with the associative loss of transcriptional regulation (i.e., reduced gene expression when inactivating an activator of transcription, enhanced gene expression when inactivating a transcriptional repressor). In the clinically important situation of the p53-E6 oncoprotein association (see above), steric blockage of the region mediating this interaction would abolish the ability of the papilloma virus product to degrade in trans the tumor suppressor. On the other hand, if both the DNAbinding and transactivation (transrepression) domains undergo conformational changes to bind tightly with their cognate DNA or protein partners, the drug might act allosterically, thereby preventing a requisite conformational alteration in a critical domain of the transcription factor (48 bind to the hybrid transcription factor and reduce or eliminate its deleterious effects on cell physiology (e.g., by inhibiting-directly or allosterically-its novel DNA-binding and transactivation properties or by promoting its degradation).
In addition to the above modes of action, some dominant negative mutant forms of "antioncogenic" transcription factors (e.g., p53) may require the design of drugs that would prevent the mutant protein (which also exhibits increased stability that facilitates its action as dominant inhibitor) from binding to the normal counterpart. This is well exemplified in cases where tumor cells contain a single mutated copy of the transcription factor that forms a heteromeric protein containing both mutant and wildtype subunits, in which the wild-type subunits are unable to exert their normal function. Alternatively, drugs might act to switch the mutant form to an activating form (by refolding the protein to its normal conformation), thereby restoring its lost tumor-suppressing capacity. Moreover, the possibility exists of developing transcription factor-modulating pharmacological agents that would inhibit progression through the cell cycle and/or induce apoptosis, potentially compensating for the loss of tumor supressor gene products involved in the operations of the cell cycle clock apparatus (p53, pRb) and/or function in the regulation of programed cell death (p53).
Inasmuch as the precise rate of cellular growth is likely to be controlled by the balance between interacting oncogene and tumor suppressor gene products, with cancer resulting from a change in this balance because of aberrant activation or increased expression of oncogenes or inactivation of anti-oncogenes, the possibility of directing structure-based or de novo drug design towards changing this balance in favor of the arrest of growth as well as manipulating individual mutant factors holds the promise of significant therapeutic advances in the future.
CONCLUSIONS
Today, computer-aided molecular modeling and structure-based or de novo drug design are rapidly evolving methodologies that have found a niche in every large pharmaceutical company as well as in many smaller biotechnology companies. In fact, several companies have been formed with the express intention of using solely these strategies for defining and exploiting "transcription" targets at the molecular level. There is no doubt that the use of these approaches in oncogenic transcription factor-targeted drug discovery, design, and optimization is an extraordinarily powerful tool that will surely expand the horizons of anticancer drug development. The ability to modulate the activity of oncogenic transcription factors directly and in a selective manner (and with acceptable toxicity profiles of the putative drugs) will allow the monitoring of tumor cell growth and progression with previously unattainable precision. This transcription factor-based therapeutic approach may enrich the anticancer drug quiver with a totally new spectrum of drugs; this will challenge cancer treatment in a fundamental way and will add significantly to the current clinical armamentarium.
